Tenpoint Therapeutics GmbH

Tenpoint Therapeutics GmbH is a commercial-ready biotechnology company developing ophthalmic and regenerative therapies aimed at the aging eye. It describes its mission as addressing major ophthalmic conditions with the highest unmet need and greatest global market potential, and it works with eye care providers on clinical and patient care. The company operates globally, with regulatory activity centred on the United States.

The company's lead product, YUVEZZI™, is a once-daily eye drop for presbyopia correction. According to the company, it is the first and only dual-agent, once-daily presbyopia-correcting eye drop to be approved by the U.S. Food and Drug Administration, receiving approval in January 2026. The approval marked the company's transition to a commercial-stage organisation.

Beyond YUVEZZI™, Tenpoint Therapeutics is developing a pipeline of novel ophthalmic and regenerative therapies in three areas: presbyopia, cataracts and geographic atrophy. Technical work spans ophthalmic drug development, ophthalmic pharmaceutical development and regenerative therapies for age-related ophthalmologic disease. The company raised $235m in Series B financing to support its programmes.